| Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit. | |
| | |
MedLine Citation:
|
PMID: 20712529 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Angiotensin-converting enzyme (ACE) inhibitors are among the most commonly used drugs in stable coronary artery disease as these agents have been proven to be effective for reducing the risk of cardiovascular morbidity and mortality. As with other drugs, individual variation in treatment benefit is likely. Such heterogeneity could be used to target ACE-inhibitor therapy to those patients most likely to benefit from treatment. However, prior attempts to target ACE-inhibitor therapy to those patients who are most likely to benefit of such prophylactic treatment in secondary prevention using clinical characteristics or the level of baseline risk appeared not to be useful. A new approach of 'tailored therapy' could be to integrate more patient-specific characteristics, such as the genetic information of patients. Pharmacogenetic research of ACE inhibitors in coronary artery disease patients is at a formative stage, and studies are limited. The Perindopril Genetic association (PERGENE) study is a large pharmacogenetic substudy of the randomized placebo-controlled European trial On Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery disease (EUROPA) trial, aimed to assess the feasibility of pharmacogenetic profiling of ACE-inhibitor therapy by perindopril. This article summarizes the recent findings of the PERGENE study and pharmacogenetic research of the treatment benefit of perindopril in stable coronary artery disease. |
| | |
Authors:
|
Jasper J Brugts; Eric Boersma; Maarten L Simoons |
Related Documents
:
|
1698369 - Soluble interleukin-2 receptors in children with kawasaki syndrome. 16087259 - Correlation between abo blood groups, major risk factors, and coronary artery disease. 16132279 - Evaluation of preclinical atherosclerosis by flow-mediated dilatation of the brachial a... 15110209 - Relation of coronary calcium scores by electron beam tomography to obstructive disease ... 17033109 - Helicobacter pylori infection in coronary artery disease. 7595119 - Ventricular gradient variability. new ecg method for detection of ischemic heart disease. 1698369 - Soluble interleukin-2 receptors in children with kawasaki syndrome. 2223119 - Morphological comparison of primary tissue failure (ptf) in porcine mitral and aortic b... 2864369 - Anastomosis of small vessels in the foot. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Pharmacogenomics Volume: 11 ISSN: 1744-8042 ISO Abbreviation: Pharmacogenomics Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-08-17 Completed Date: 2010-12-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897350 Medline TA: Pharmacogenomics Country: England |
Other Details:
|
Languages: eng Pagination: 1115-26 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Erasmus MC Thoraxcenter, 's Gravendijkwal 230, Rotterdam, The Netherlands. j.brugts@erasmusmc.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin-Converting Enzyme Inhibitors
/
administration & dosage,
therapeutic use* Coronary Artery Disease* / genetics, prevention & control Haplotypes Humans Perindopril / administration & dosage, therapeutic use* Pharmacogenetics* Randomized Controlled Trials as Topic Recurrence / prevention & control Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 82834-16-0/Perindopril |
| Comments/Corrections | |
Comment In:
|
Pharmacogenomics. 2010 Oct;11(10):1345-8
[PMID:
21047196
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal ca...
Next Document: IFN-beta pharmacogenomics in multiple sclerosis.